|
Cognetivity Neurosciences
reaches commercial agreement
with Emirates Health
Services
(Vancouver,
B.C.) -
Cognetivity Neurosciences
Ltd. (the “Company” or
“Cognetivity”) (CSE: CGN;
OTCQB: CGNSF; FWB: 1UB)
today announced that it has
reached a commercial
agreement with Emirates
Health Services (“EHS”) for
the Company’s Integrated
Cognitive Assessment (“ICA”)
technology to be deployed as
a screening tool for
cognitive impairment
throughout the United Arab
Emirates (“UAE”). Based in
Dubai, EHS is the main
federal provider of public
healthcare services in the
UAE. It functions as the
operating arm of the
country’s Ministry of Health
and Prevention, running
hundreds of healthcare
centers and hospitals across
the UAE and handling
hundreds of thousands of
outpatient visits each year.
At the heart of the
partnership between EHS and
Cognetivity lies CognICA™ –
Cognetivity’s flagship
medical device, powered by
the Company’s ICA medical
device technology which has
recently been registered
with the UAE Ministry of
Health and cleared for
medical use across the UAE.
Under the terms of the new
agreement, CognICA will be
deployed in EHS-run clinics
as a screening tool for
measuring patients’ brain
health and streamlining the
detection of cognitive
impairment.
The aim
of this large-scale
implementation is to enhance
the timely diagnosis of mild
cognitive impairment and
dementia. Dementia is a
serious and growing
healthcare problem all over
the world, with more than 55
million people currently
living with the condition,
but it poses a particular
challenge to the UAE. A
study published this year in
The Lancet Public Health
forecasts that the UAE will
experience the
second-highest percentage
increase worldwide in the
number of people living with
dementia by 2050.
The
decision by EHS to deploy
Cognetivity’s cutting-edge,
AI-powered technology to
tackle the growing problem
of dementia is
characteristic of the
country’s innovative and
technology-led approach to
achieving excellence in
public healthcare. The
country is known for being
ambitious and proactive in
pursuing its goal of
developing a world-leading
healthcare system: the speed
and high uptake of its
Covid-19 vaccination program
drew international attention
last year, while 2021 also
saw the UAE become the
second country in the world
(behind the US) to approve
the novel Alzheimer’s drug
Aduhelm™ for clinical
treatment.
The ICA is
perfectly suited to the task
of population-wide screening
in the UAE. It is a short
and simple test, delivered
on a tablet, that can be
taken by a patient remotely
or in person, without the
need for administration by a
specialist. This means that
large-scale rollout of
CognICA can be achieved very
rapidly and does not need to
be limited to specialist
clinics. Due to its absence
of learning effect and
capacity to integrate with
electronic health record
systems, CognICA provides an
end-to-end cognitive testing
solution that can be applied
throughout the patient
pathway to greatly improve
the efficiency of diagnosis
and treatment.
Dr
Sina Habibi, Cognetivity’s
CEO, said: “We’re hugely
excited about this latest
deployment of the ICA and
thrilled to confirm another
major deal in the Middle
East. To tackle the massive
global problem of dementia,
we have to begin cognitive
testing on a larger scale
than ever before. The ICA is
the perfect tool in every
way for this job and this
latest implementation paves
the way for further
large-scale deployments in
the future, which is
immensely exciting.”
“What’s fantastic about the
health authorities in the
UAE is that they clearly
appreciate the value of
innovation in improving
healthcare outcomes,” he
continued. “They have a bold
vision for the future of
healthcare in the region and
are not afraid to take bold
steps in making that a
reality. In this regard, our
attitudes are very closely
aligned. I’m confident that
this deployment will be a
great success for the people
of UAE and Cognetivity.”
Cognetivity is a
technology company that has
created a cognitive testing
platform for use in medical,
commercial and consumer
environments.
PRINT
THIS ARTICLE
|